Summary & Overview
HCPCS J1444: Ferric Pyrophosphate Citrate Injection, 0.1 mg
HCPCS Level II code J1444 represents a unit of ferric pyrophosphate citrate powder for injection, providing 0.1 mg of elemental iron. This parenteral iron product is used in settings requiring intravenous iron replacement or supplementation, commonly administered during dialysis sessions or in outpatient infusion centers. Nationally, accurate coding for iron therapies affects clinical supply management, claims processing, and payer coverage determinations for patients requiring intravenous iron.
Key payers in the national landscape include Aetna, Blue Cross Blue Shield, Cigna Health, UnitedHealthcare, and Medicare. Readers will find an overview of coverage and payment considerations for this HCPCS Level II code, clinical context for use in dialysis and infusion settings, and common billing themes such as unitization and site-of-service implications. The publication also outlines benchmarking points, recent policy updates where available, and operational notes relevant to billing and revenue cycle teams.
This summary equips clinicians, coders, and reimbursement analysts with the core facts about J1444, clarifies where the service is typically delivered, and points to the types of payer policies and billing practices that most affect reimbursement and documentation workflows. Data not available in the input will be noted where applicable.
Billing Code Overview
HCPCS Level II code J1444 describes an injection of ferric pyrophosphate citrate powder, providing 0.1 mg of elemental iron per billed unit. This code represents a parenteral iron preparation intended for systemic administration.
Service Type: Injection (intravenous or as clinically indicated)
Typical Site of Service: Outpatient infusion center, dialysis facility, or hospital outpatient department
Data not available in the input.
Clinical & Coding Specifications
Clinical Context
A 54-year-old patient with end-stage renal disease (ESRD) on maintenance hemodialysis presents for routine in-center dialysis. The patient has documented iron deficiency related to ongoing blood losses and inflammatory-mediated functional iron deficiency despite prior oral iron therapy. The clinician orders intravenous administration of ferric pyrophosphate citrate to maintain hemoglobin and reduce erythropoiesis-stimulating agent requirements. The product described by billing code J1444 (injection, ferric pyrophosphate citrate powder, 0.1 mg of iron) is prepared per manufacturer instructions and administered via the dialysis circuit during each hemodialysis session by a dialysis nurse under standing order or direct provider authorization. Vital signs are monitored before, during, and after infusion; the dialysis nursing note documents lot number, dose, route (via dialysis catheter/arterial line), and any adverse reactions. Billing is submitted under the outpatient dialysis encounter with J1444 reported per 0.1 mg dosing units as applicable, and appropriate place-of-service and modifier usage recorded when required.
Coding Specifications
| Modifier | Description | When to Use |
|---|---|---|
22 | Increased procedural services | When work, time, or complexity substantially exceeds typical requirements for administration, documented and justified. |